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Summary 
Polyspecificity is a well-known property of the anti-DNA antibodies produced by autoimmune 
animals.  In our search  for antigen  targets  of anti-DNA  antibodies within  tissue extracts,  we 
identified a 32-kD polypeptide that  was recognized by a large panel of anti-DNA  antibodies. 
Direct sequencing of this protein disclosed its identity with DNase I. 22 monoclonal anti-DNA 
antibodies bound to DNase I in direct and competitive immunoassays; out of 15 autoantibodies 
that did not bind DNA, none had the ability to bind DNase I. The ability of anti-DNA antibodies 
to interfere with DNase I enzymatic activity was evaluated in an assay based on the enzyme 
digestion of phage double strand DNA. Six monoclonal anti-single strand DNA antibodies that 
did not bind double strand DNA were tested in this assay. Three out of six inhibited DNase 
I-mediated  digestion of phage DNA.  The interaction  of anti-DNA  antibodies with DNase I 
was further investigated by testing their ability to bind a synthetic peptide that corresponds to 
the catalytic site of the molecule. 4 out of 22 anti-DNA antibodies bound the active site peptide; 
two of these had been shown to inhibit  DNase I enzymatic activity.  This report  shows that 
anti-DNA  antibodies recognize both DNA and its natural  ligand  DNase I.  Some anti-DNA 
antibodies inhibit DNase I enzymatic activity, thus displaying the potential to modulate DNA 
catabolism.  The  dual  specificity of anti-DNA  antibodies  offers a clue for understanding  the 
mechanisms  that  lead to  anti-DNA  antibody production  in  autoimmune  animals. 
I 
dentification of the events leading to the production of anti- 
DNA antibodies in individuals with systemic lupus ery- 
thematosus has been enigmatic. Genetic studies of anti-DNA 
antibodies from lupus-prone mice suggest that the produc- 
tion of anti-DNA antibodies is antigen driven. However, nat- 
uraUy occurring nucleic acids and, in particular,  double strand 
DNA (dsDNA) 1, are only weakly immunogenic  (1). More- 
over, antibodies produced after immunization with DNA do 
not cross-react with multiple autoantigens like their patho- 
genic counterparts (2-9), nor do they produce lupus lesions 
(10, 11). In view of this promiscuous reactivity of lupus au- 
toantibodies, we reasoned that self proteins, rather than nu- 
cleic acids, could be responsible for eliciting a lupus antibody 
response in genetically susceptible and/or immunologically 
impaired individuals.  To test this hypothesis,  our goal was 
to identify candidate  proteins. 
In our search for cross-reactive proteins of lupus autoanti- 
bodies, we identified a 32-kD polypeptide that was specifically 
recognized by a large panel of anti-DNA antibodies. On sub- 
sequent analysis,  this peptide was determined to be DNase 
1 Abbreviations used in this paper: dsDNA, double strand DNA; ssDNA, 
single strand DNA. 
I.  Furthermore,  a subset of anti-DNA antibodies inhibited 
the functional activity of this enzyme; epitope mapping of 
these antibodies localized the binding to a positively charged 
sequence corresponding to the catalytic site of the molecule. 
This novel antigenic specificity of anti-DNA antibodies pro- 
vides clues to understanding the events leading to the produc- 
tion of anti-DNA antibodies in autoimmune individuals, and 
it raises the possibility that the direct interaction of autoanti- 
bodies with constitutive enzymes may influence the autoim- 
mune/inflammatory  response. 
Materials and Methods 
Antigens and Buffers.  (a) Preparation of DNase I. Bovine DNase 
I, RNase-free, was purchased from Boehringer Mannheim (Mann- 
heim, Germany).  (b) Preparation of glomerular  extract.  Human 
glomerular  extract was prepared as described elsewhere in detail 
(10). Briefly, human glomeruli were lysed in cold hypotonic buffer 
(20 mM Tris, pH 7.4) containing a cocktail of protease inhibitors 
(PMSF, leupeptin, aprotinin, pepstatin, and antipain), reduced with 
2-mercaptoethanol (1% final vol), and treated with SDS (3% final 
vol). (c) Preparation of polynucleotides. Single strand DNA (ssDNA) 
a:ad dsDNA were prepared as described elsewhere in detail (10-12). 
Poly(dT) was purchased from Sigma Chemical Co. (St. Louis, MO). 
(d) Chelex 100 treatment.  Chelex 100 resin, a chelating agent for 
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Sigma Chemical Co. and used according to the manufacturer's in- 
structions. The buffers or the antigen and antibody solutions (100 
ml/5 g resin) were absorbed three times on Chelex 100 to ensure 
complete removal of divalent cations. 
Antibodies.  Murine monodonal anti-DNA antibodies (H241, 
H130, H102, P168,  27, D, 15/9,  110/13,  512, A, and 62/11), as 
well as anti-DNA-negative autoantibodies  (136, A, C, 56, 35, 21/7, 
85,  5/5, 100, and 28/12), were prepared from spleen cells of im- 
munized MRL-lpr/lpr mice (3,  5,  13,  14). 
Antibodies 21/6, 21/10, 21/12, 21/15, 21/17, and 21/23 were 
obtained from the fusion of splenocytes  of BALB/c mice injected 
with the ribonucleoprotein-mimicking idiotype light chain G, as 
elsewhere described in detail (15). The anti-DNA antibodies were 
all IgM with the following exceptions: monoclonal antibody H241 
(IgG2,) and antibody H102 (IgG2b). The anti-DNA-negative au- 
toantibodies  were all  IgM  with  a  few exceptions:  antibody C 
(IgG2a), antibody 28/12 (IgG2b), and antibody 35 (IgG3). 
Human  monoclonal anti-DNA  antibodies  (Hy2, Hy8, Hy9, 
Hyl0, and Hy12) were derived by EBV transformation of B cells 
obtained from patients with systemic lupus. Human anti-DNA- 
negative autoantibodies (A2, A10, A77, and B19.7) were obtained 
in Dr. R. S. Schwartz's laboratory (New England Medical Center, 
Boston, MA). All the human monoclonal anti-DNA antibodies, 
as well as control autoantibodies, were IgM. 
The mouse IgM monoclonal anti-DNase I antibody was obtained 
from the fusion of splenocytes of a BALB/c mouse immunized with 
bovine DNase I. 
Isotype-matched murine Ig was purchased from Cappel Labora- 
tories (Cochranville, PA). 
Preparation and characterization of IdssDNA and IddsDNA are 
described elsewhere in detail (16). Briefly, the two antibody prepa- 
rations were derived from a patient with active lupus nephritis. 
IdssDNA was prepared using an oligo(dT)-cellulose column (Phar- 
macia LKB, Piscataway, NJ); the antibody population had no anti- 
dsDNA  activity. 
IddsDNA was prepared using a native dsDNA-cellulose  column 
(Pharmacia  LKB);  the  preparation  preferentially reacted  with 
dsDNA. 
Polyclonal anti-DNA antibodies were isolated  from the serum 
of eight  different patients  with  active  lupus  nephritis  with  an 
oligo(dT)-cellulose column. The preparations obtained retained both 
anti-ss  and anti-dsDNA  activity. 
To avoid any interference by DNA--anti-DNA complexes within 
individual antibody preparations,  anti-DNA antibodies were treated 
with micrococcal nuclease,  and both double-stranded and single- 
stranded exonucleases. 
Briefly, 10 #g of individual antibodies 21/6, 21/12, H241, H130, 
H102, Hy2, Hy9, and Hy12 were first digested with micrococcal 
nuclease (Sigma Chemical Co.) in 50 mM Tris, 5 mM MgC12, pH 
7.5, and the reaction was stopped by the addition of 10 mM EDTA. 
Further digestions were obtained with  exonuclease  III (double- 
stranded 3'-5' exonuclease) (Promega Corp., Madison, WI), 20 U 
in 50 mM Tris, 5 mM MgClz, 5 mM dithiothreitol, 20 mM KC1, 
50 #g/ml BSA, pH 7.5  (1 h, 37~  and exonuclease  VII (5'-3' 
and Y-5' exonuclease)  (Promega Corp.), 0.4 U in 70 mM Tris, 8 
mM EDTA,  10 mM/3-mercaptoethanol,  50/~g/ml BSA, pH 8. 
The antibody preparations were then absorbed on Chelex 100 and 
extensively dialyzed against Chelex 100-treated 20 mM Tris, pH 
7.5. Ethidium bromide staining of phenol-extracted digested anti- 
bodies (50 #g/lane of an agarose get) did not reveal any DNA 
fragment. 
Western Blot.  The glomerular extracts were separated on a 10% 
SDS-PAGE in reducing conditions and transferred to nitrocellu- 
lose or polyvinyldifluoride membranes (Immobilon P;  Millipore 
Corp., Bedford, MA). Filters were saturated by 1-h incubation at 
room temperature in 50 mM Tris, 150 mM NaC1, 5% dry nonfat 
milk. The same buffer was used for antibody dilutions and washing. 
Purified mAbs at 20/zg/ml or polyclonal Ig at 10/zg/ml were in- 
cubated on filters for 4 h at room temperature. After washings, 
alkaline phosphatase--conjugated goat anti-human IgG, anti-human 
IgM  (Sigma  Chemical Co.),  or goat anti-mouse  IgG-IgA-IgM 
(Boehringer Mannheim) were added and incubated overnight at 
4~  The immunoreactive bands were visualized  using 5-bromo- 
4-chloro-indoxyl-phosphate and nitroblue tetrazolium as substrate 
(17). Ethidium bromide staining of phenol-extracted dry nonfat 
milk did not reveal the presence of DNA. 
Microprotein Sequencing.  The protein of interest (32 kD) was 
partially purified from human glomerular extract, using several steps 
of ion exchange chromatography (on DEAE-Sephadex and carboxy- 
methyl-Sephadex [Sigma Chemical Co.]). The fractions enriched 
for the 32-kD polypeptide were pooled and concentrated using Cen- 
tricon microconcentrators (Amicon, Beverly, MA) (10,000 mol wt 
cut-off). The concentrated material was precipitated with ice-cold 
20% TCA for 1 h on ice. The pellet, obtained after centrifugation, 
was washed twice with cold acetone, dried in a vacuum centrifuge 
(Univepo 150 H; Uniequip,  Martinswed,  Germany), and resus- 
pended in a small volume of 50 mM ammonium bicarbonate, 4 M 
urea, 2% SDS, pH 7.4. 
The purified extract was run  on a  12.5%  SDS-PAGE under 
reducing conditions and transferred to polyvinyldifluoride mem- 
branes (Immobilon, P; Millipore Corp.), using  10 mM 3-cyclo- 
hexylamino-l-propane sulfonic acid (CAPS), pH 11. The band of 
interest was then excised and subjected  to microprotein sequence, 
according to P. Matsudaira (18), using a sequencer  (Applied  Bio- 
systems,  Foster City, CA). 
Immunoprecipitation.  Purified glomerular extract and DNase I 
(Boehringer Mannheim)  were labeled  with  112s, using  a bead- 
immobilized preparation of lactoperoxidase and glucose-oxidase (En- 
zymobead Solid Phase Radioiodination Kit; Bio-Rad Laboratories, 
Richmond, CA). The labeled material was diluted in cold lysis buffer 
(20 mM Tris, 150 mM NaC1,  10 mM EDTA, 1% NP-40, 0.2% 
SDS,  pH  7.5,  containing a mixture of protease inhibitors) and 
precleared  twice by the addition of one-fifth the volume of Pan- 
sorbin (Calbiochem-Novabiochem, San Diego, CA). 
Immunoprecipitations were carried out by overnight incubation 
of the individual antibodies (20/~g of  either human or mouse mAbs, 
10/zg of human polyclonal Ig) with aliquots of labeled extract or 
DNase I (106 TCA precipitable  cpm/experiment). 50 #1 of packed 
Sepharose  beads  (Pharmacia LKB), previously coupled to either 
rabbit anti-mouse IgM (Litton Bionetics, Kensington, MD) or goat 
anti-human  IgM  (Calbiochem-Novabiochem), or,  alternatively, 
50/~1 of protein A-Sepharose beads, were added to individual tubes, 
and the samples were rotated for I h at 4~  The beads were exten- 
sively washed five times with cold washing buffer (20 mM Tris, 
15 mM EDTA, 500 mM NaCI, 1% NP-40, 1% SDS, pH 7.5, con- 
taining a mixture of protease inhibitors). For absorption experi- 
ments, radiolabeled glomerular extract was repeatedly absorbed on 
insolubilized antibodies, until no radioactivity could be eluted from 
the beads. The absorbed glomerular extract was then immunopre- 
cipitated as above described.  The immunoprecipitates were eluted 
in sample buffer and analyzed by SDS-PAGE. Dried gels were au- 
toradiographed at  -70~  with an x-ray intensifying screen. 
Peptide Synthesis.  Synthetic peptides were obtained by solid phase 
synthesis,  using  Fmoc-protected amino  acids,  according to  the 
method of Merrifield as modified by Atherton (19). The peptides 
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peptides,  which had as a cysteine the NH2- and COOH-terminal 
residue,  were oxidized by oxygen bubbling. 
ELISA.  DNase I and peptides were used  at a concentration 
of 10/zg/ml to coat polystyrene  plates (Nunc, Roskilde, Denmark). 
After blocking for 1 h with 3% BSA in PBS, the antibodies, diluted 
in 1% BSA, 0.05% Tween in PBS, were added and incubated for 
4 h at room temperature. The plates were then washed once with 
1%  Tween in  PBS and twice with PBS.  Alkaline  phosphatase- 
conjugated goat anti-human IgG or IgM (Sigma Chemical Co.), 
goat anti-mouse IgG-IgA-IgM, or anti-mouse IgM (Boehringer 
Mannheim) in diluting buffer were then added and incubated over- 
night at 4~  After washings,  the bound enzymic activity was mea- 
sured with p-nitrophenyl-phosphate (Sigma  Chemical Co.). 
For competitive assays, the amount of antibody that gave 50% 
of the maximum binding to the antigen on the solid phase  was 
preincubated with different amounts of competitors or buffer for 
I h at 37~  and then transferred to the antigen-coated plates. The 
assay was then carried on as the direct binding assay. Alternatively, 
antibody preparations were Chelex 100-treated to remove divalent 
cations. ELISA plates were coated with DNase I (10/~g/ml in Chelex 
100-treated 20 mM Tris, pH 7.5), blocked with 3% BSA in 250 
mM EDTA for 1 h at room temperature, and washed with 0.05% 
Tween in Chelex 100-treated 20 mM Tris, pH 7.5 (buffer A). Buffer 
A was also used for antibody dilutions and washings.  Bound enzy- 
matic activity was revealed as described above. The direct binding 
and competitive ELISA for antibody against ssDNA, dsDNA, and 
polynucleotides have been described in detail elsewhere (3, 5,  12, 
13). Ethidium bromide staining of phenol-extracted BSA did not 
reveal the presence of DNA. 
DNase I Functional Activity.  Hind III-digested )x DNA, (Bio- 
Pad Laboratories,  Inc.) was  treated with  DNase I  (Boehringer 
Mannheim). Briefly, 3/zg of DNA were incubated with 1/~g of 
DNase I in 50 mM Tris-HC1,  1 mM MgC12, 0.1% BSA, pH 7.5 
for 20 min on ice. The reaction was  then stopped with  10 mM 
EDTA.  In inhibition experiments, 10/~g of anti-DNA antibodies 
or control Ig were preincubated with 1/~g of DNase I for 20 rain 
on ice. The assay was then carried out as described above. Digested 
DNA was run on a 1% agarose gel. The gel was then stained with 
2/~g/ml of ethidium bromide and photographed under UV light. 
Results 
Reactivity  of Anti-DNA  Antibodies  with a 32-kD Polypelo- 
tide, Highly Homologous to DNase I.  To select candidate au- 
toantigen proteins, our overall strategy was to evaluate a large 
panel of anti-DNA antibodies from MRL-lpr/lpr mice and 
SLE patients  for reactivity with tissue extracts (as  a source 
of potential protein autoantigens). After a brief survey, it be- 
came apparent that, although other bands were often observed, 
reactivity of anti-DNA  antibodies  with  a  32-kD  polypep- 
tide was universal (see below).  An example of this observa- 
tion for anti-DNA  antibodies derived from human lupus is 
illustrated  in Fig.  1.  Our  aims were to identify the nature 
of this/these  protein(s) and to further examine the interac- 
tion between anti-DNA antibodies and this/these protein(s). 
By two-dimensional gel electrophoresis, a single immuno- 
reactive spot was identified. The 32-kD polypeptide was iso- 
lated and  subjected  to partial  aminoacid  sequence analysis. 
Its NH2-terminal sequence was 94% homologous to bovine 
DNase  I  (15/16  amino  acids). 
The putative identity of the 32-kD  peptide  as  DNase  I 
Figure  1.  Binding  of affinity-purified  human anti-DNA antibodies to 
glomerular extract. Human glomerular extract was run on a 12% SDS 
gel under reducing conditions and transferred  to nitrocellulose.  The filters 
were probed with two anti-DNA polyclonal preparations, anti-ssDNA, 
IdssDNA, and anti-dsDNA, lddsDNA (lanes 2 and 3), isolated from a 
patient with systemic  lupus and with normal human polyclonal  Ig (lane 4). 
Lane 1 is a control lane in which only the second  antibody (alkaline  phos- 
phatase-conjugated goat anti-human Ig) was used. Anti-DNA antibodies 
detect a band of 32 kD; no reactivity is detected with normal human Ig. 
was confirmed by the following observations: A routine mono- 
clonal anti-DNase I and the anti-DNA antibodies immuno- 
precipitated a 32-kD band in the radiolabeled glomerular ex- 
tract.  An example is given in Fig.  2  (lanes 5  and 6). When 
radiolabeled glomerular extract was absorbed on immobilized 
anti-DNase antibody before immunoprecipitation,  the anti- 
DNA antibodies did not recognize the 32-kD protein (Fig. 
2, lane 7). Conversely, after absorption with anti-DNA anti- 
bodies, the monoclonal anti-DNase did not immunoprecipi- 
tate the 32-kD protein (Fig. 2, lane 8). The protein immu- 
noprecipitated by the monoclonal anti-DNase was recognized 
in Western blot by anti-DNA antibodies (data not shown). 
The anti-DNA antibodies that reacted with the 32-kD band 
also recognized labeled DNase I (Fig. 3). Finally, peptide maps, 
generated from the isolated 32-kD band, and purified DNase 
I were identical (data not shown). Taken together, these results 
suggest that  the immunoreactive protein in the cellular ex- 
tract  is DNase  I. 
Anti-DNase I Activity Is Specific and Common among Anti- 
DNA Antibodies.  To examine the specificity of these inter- 
actions, an unselected panel of monoclonal anti-DNA anti- 
bodies  (17  mouse,  5  human)  were tested for anti-DNase  I 
activity by  direct  binding  and  competition  immunoassays 
(Table 1). All 22 anti-DNA mAbs bound to solid phase DNase 
I; by comparison,  binding was not observed for any of the 
autoantibodies  that  did  not  bind  DNA  (10 murine  and  5 
human  mAbs),  nor  by  isotype-matched  control  Ig.  The 
specificity of the results was confirmed by competitive inhi- 
bition in each case.  The compiled results are given in Table 
1799  Puccetti et al. Hgure 2.  Immunoprecipitation  of I12S-labeled  glomerular  extract. Glo- 
merular extract was labeled with 112s  and incubated with individual anti- 
bodies (106 TCA precipitable  cpm/antibody). The complexes  were  precipi- 
tated by insolubilized  anti-mouse Ig or protein  A. (Lane  1) Mouse  polyclonal 
anti-DNase I antibodies. (Lane  2) Mouse monoclonal anti-DNA negative 
IgG antibody. (Lane  3) Mouse monoclonal anti-DNA negative IgM anti- 
body. (Lane  4) human polyclonal  anti-DNA negative  IgG antibodies. (Lane 
5) Mouse  monoclonal  anti-DNase  I. (Lane  6) Human polyclonal  anti-ssDNA 
antibody, IdssDNA. The two anti-DNase I antibodies (lanes 1 and 5) and 
the anti-DNA antibody, IdssDNA (lane  6) detect a band of the same mo- 
lecular weight (32 kD), which is not recognized by control antibodies 
(lanes 2-4). For absorption experiments, radiolabeled  glomerular extract 
was repeatedly  absorbed  with insolubilized  antibodies (mouse monoclonal 
anti-DNase I antibody  (lane 7) or polyclonal  anti-DNA antibody, IdssDNA 
(lane 8), until no labeled material could be eluted from the beads. The 
absorbed extract (106 TCA precipitable cpm/antibody) was then immu- 
noprecipitated with IdssDNA (lane 7) or mouse monoclonal anti-DNase 
I antibody (lane  8). After absorption no 32-kd band could be immunopre- 
cipitated by anti-DNA  or anti-DNase I antibodies. 
2.  The binding  of the  anti-DNA  antibodies  to DNAase  I 
was  also shown by Western blot and immunoprecipitation 
techniques (Table 2). Binding to DNase I was also observed 
among 8/8 human polyclonal anti-DNA  antibody prepara- 
tions derived from the serum of lupus patients;  however, it 
was  not  present  among  either  Ig  that  did  not  bind  DNA 
from the same serum, or Ig isolated from normal human sera 
(not  shown). 
We next considered the possibility that DNA was present 
in  the  assays  and  affected the  results  (i.e.,  anti-DNA  anti- 
body binding to the DNA-DNase  I complex). As DNase 
I binding to DNA is strictly calcium and magnesium depen- 
dent (20-23), the assays were performed in Tris buffer treated 
with chelating agents (Chelex 100). Under these conditions, 
DNase I cannot bind and digest DNA. However, all the anti- 
DNA antibodies retained activity against DNase I. Moreover, 
the DNase  I-binding  ability of mAbs  21/6,  21/12,  H241, 
H130, H102, Hy2, Hy9, and Hy12 was not significantly re- 
duced by the antibody treatment with DNA-hydrolyzing en- 
zymes, micrococcal nuclease, and double-stranded and single- 
stranded  exonucleases  (data  not  shown). 
A  Subset of  Anti-DNA Antibodies Reacts with the Functional 
Domain  of DNase I and Inhibits Enzymatic Activity.  To test 
whether anti-DNA antibodies interfere with DNase I enzy- 
matic activity, it was necessary to circumvent possible inter- 
actions between anti-DNA antibodies and DNA in the assay. 
For  this  purpose,  six  monoclonal  anti-ssDNA  antibodies 
without  detectable anti-dsDNA  antibody activity were se- 
lected, and their capacity to inhibit DNase I-mediated diges- 
tion of phage dsDNA  was evaluated. As illustrated in Fig. 
4, three of six mAbs were observed to interact with DNase 
I  and  to inhibit  the  digestion  of DNA. 
Based on these results, we postulated that some of the anti- 
DNA antibodies may bind to the functional domain of DNase 
I  and  inhibit  its  enzymatic activity.  Alternatively,  interac- 
tions with other residues could alter the conformation of the 
enzymatic site to influence enzymatic activity. To address these 
possibilities, we took advantage of the observations of D. Suck 
and co-workers (22), who demonstrated that part of the ac- 
tive site ofDNase I is formed by a loop corresponding to the 
sequence 73-78: Arg-Asn-Ser-Tyr-Lys-Glu. Three closely re- 
lated peptides were synthetized as follows: adding two alanine 
residues as NH2- and COOH-terminal  amino acids (peptide 
a);  adding  two cysteine residues  as NH2-  and  COOH-ter- 
minal amino acids (peptide b); adding two cysteine residues 
as NH2- and COOH-terminal  amino acids and substituting 
Arg 73  and Lys 77 with  alanine  (peptide c).  The cysteine- 
containing peptides were then oxidized so that a cyclic pep- 
tide could be formed whenever cysteine was the NH2- and 
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Figure 3.  Immunoprecipitation of I12S-labeled  DNase 
I. DNase I was labeled with 112s  and incubated with in- 
dividual antibodies. The immune complexes  were precipi- 
tated by the  addition of insolubilized anti-human  or 
anti-mouse Ig. (Lane 1) Mouse polyclonal  anti-DNase I 
serum. (Lane 2) Mouse monoclonal anti-DNase I anti- 
body. (Lane 3) Anti-DNA negative mouse monoclonal 
IgM antibody 21/7. (Lane  4) Anti-DNA negative  mouse 
monoclonal  IgM antibody 136. (Lane  5) Anti-DNA nega- 
tive mouse monoclonal IgG antibody (C). (Lane  6) Anti- 
DNA negative human monoclonal IgM antibody A2. 
(Lane 7) Anti-DNA  negative human monoclonal IgM 
antibody A10. (Lane 8) Human polyclonal anti-DNA 
negative  IgG antibodies. (lane 9) Human monoclonal  anti- 
DNA  antibody  Hy12. (Lane I0)  Mouse monoclonal 
anti-DNA antibody H130. (Lane  11) Mouse monoclonal 
anti-DNA antibody  P168. (Lane  12) Mouse  monoclonal  anti- 
DNA antibody H241. (Lane 13) Human polyclonal  anti- 
ssDNA antibody, IdssDNA. (Lane  14) Human polyclonal 
anti-dsDNA antibody, IddsDNA. Table  1.  Anti-DNase I  Activity of Anti-DNA  mAbs 
ssDNA  dsDNA  DNase  I  peptide a  peptide b 
Mouse  mAbs 
H241  0.20*  0.16"  2.5*  0.90~  5.0*  5.0* 
H130  0.15  _ s  5.0  0.70  -  - 
H102  0.20  -  5.0  0.40  -  - 
P168  0.60  -  2.5  0.65  5.0  5.0 
27  2.00  -  5.0  0.30  +  _+ II 
D  0.16  -  5.0  0.35  -  - 
15/9  1.25  -  2.5  0.50  -  - 
110/13  0.40  2.00  3.0  0.55  5.0  5.0 
512  1.00  -  2.5  0.48  _+  _+ 
62/12  1.25  -  5.0  0.73  _+  _ 
21/6  0.40  2.00  5.0  0.60  -  - 
21/10  0.02  -  5.0  0.56  _+  _+ 
21/12  0.08  -  8.0  0.34  -  - 
21/15  0.02  -  8.0  0.40  -  - 
21/17  0.40  -  2.0  0.75  _  _+ 
21/23  0.02  0.40  2.0  0.85  __  _+ 
Human  mAbs 
Hy  2  1.00  -  5.0  0.45  _+  _ 
Hy  8  0.40  -  5.0  0.38  -  - 
Hy  9  0.20  -  2.5  0.58  -  - 
Hy  10  0.10  -  2.5  0.54  _+  _+ 
Hy  12  0.60  -  4.0  1.00  2.5  2.5 
* Micrograms of liquid phase  inhibitor required for 50%  inhibition in competitive homologous assays. 
* A 405  for 10 #g/ml mAb in direct-binding assay. 
S -  indicates  no binding to the antigen on the solid phase. 
Pl +_  indicates  direct binding, but >10/~g/ml inhibitor required for 50%  inhibition in competitive immunoassays. 
COOH-terminal  residue.  The cyclic peptides should, there- 
fore, closely approximate the tertiary structure  of the loop. 
The anti-DNA  antibodies were then tested for reactivity 
against the peptides. As shown in Table 1, four of the anti- 
bodies bound peptides a and b in direct and competitive ELISA; 
Table  2.  Anti-DNase I  Activity of mAbs 
Dot  blot/  Immuno- 
ELISA  Western  blot  precipitation 
Anti-DNA  22/22  20/20  17/17 
autoantibodies 
Non-anti-DNA  0/15  0/15  0/10 
autoantibodies 
Isotype-matched Ig  0/35  0/25  0/10 
Results are given as number of antibodies binding DNase I by ELISA, 
dot blot, or Western blot, and immunoprecipitation over the number 
of antibodies tested. 
none  of the.m  reacted with  peptide c.  Two  of the peptide- 
binding antibodies (P168 and Hy12) had been shown  to in- 
hibit DNase I functional activity. Moreover,  the binding of 
mAbs  110/13  and Hy12  to  solid phase DNase  I  was  com- 
peted by peptide a and, to a lesser extent, by peptide b, while 
peptide c  had no effect at all (Fig.  5). These results indicate 
that a subset of anti-DNA  antibodies specifically recognizes 
a  sequence  contained  in  the  active site of the  enzyme. 
Discussion 
This report indicates that autoantibodies, derived from in- 
dividuals with lupus and initially selected for anti-DNA an- 
tibody activity, interact in an antigen-specific manner  with 
DNase I. This appears to be a common property of anti-DNA 
antibodies,  present  among  both  murine  and  human  Ig  (as 
well as in serum from individuals with lupus). The anti-DNase 
activity is specific, and, in some cases, binding of DNase in- 
terferes  with  its  enzymatic  activity. 
DNase I is a double-stranded specific endonudease that hydro- 
lyzes DNA  to form short oligonucleotides having 5'-phosphate 
and Y-hydroxyl termini.  It requires the presence of divalent 
cations  (Ca z+  and  Mg 2+)  for  the  cleavage reaction. 
1801  Puccetti et al. Figure  4.  Inhibition of DNase I enzymatic activity. HindlII-digested 
~, DNA was incubated with DNase I, and the digestion was stopped by 
the addition of EDTA. Digested DNA was run on a 1% agarose gel, which 
was  then  stained with ethidium bromide and photographed  under  UV 
light. (Lane 1) HindlIl-digested X DNA. (Lane 2) HindlII-digested X DNA 
treated with DNase I. (Lane 3-8) HindlIl-digested X DNA treated with 
DNase I preincubated with Hy12 (lane 3),  P168  (lane 4), H130 (lane 5), 
H102 (lane 6), 21/10 (lane 7) and 21/15 (lane 8). Preincubation of DNase 
I with mAbs Hy12,  P168,  and H130 blocked the ability of the enzyme 
to digest  the substrate. 
The crystal structure of the enzyme has recently been solved 
at high resolution (22). Electrostatic interactions play a prom- 
inent role in the DNA binding. In particular, the 2-A  reso- 
lution structure of DNase I, complexed to a short oligonu- 
cleotide (24),  showed that  an exposed peptide loop (Arg- 
Asn-Ser-Tyr-Lys-Glu) fits tightly in the minor groove of  DNA. 
These residues and five additional arginine and lysine residues 
form salt  bridges  with  phosphate  groups  of both  strands 
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Figure  5.  Inhibition of antibody 110-13 binding to DNase I. mAb 110-13 
was preincubated with different amounts of peptide a (Ala-Arg-Asn-Ser- 
Tyr-Lys-Glu-Ala), peptide b  (Cys-Arg-Asn-Ser-Tyr-Lys-Glu-Cys), or pep- 
tide c (Cys-Ala-Asn-Ser-Tyr-Ala-Cys) for 1 h at 37~  and then transferred 
to a DNase I-coated plate.  Bound antibody was detected by an alkaline 
phosphatase-labeled  anti-mouse antiserum.  Results are expressed as per- 
cent inhibition: 100  -  I100 x  absorbance  [antibody  +  peptide]/absorbance 
[antibody  +  buffer]l. 
flanking the minor groove. No contacts are formed between 
DNase I and the major groove. The enzyme interacts with 
an extensive region of the B-type DNA duplex over a total 
of 6 bp  (34  A)  (25). 
We took advantage of these features to confirm specificity 
and map the binding site of a subgroup of anti-DNA anti- 
bodies. Using synthetic peptides corresponding to the active 
site  of the enzyme, the epitope recognized by a subgroup 
of these autoantibodies on DNase I was mapped to the se- 
quence Arg-Asn-Ser-Tyr-Lys-Glu.  The substitution of the two 
positively charged amino acids with  alanine abolished the 
binding, thereby suggesting a prominent role of electrostatic 
interactions in the antibody recognition. In this regard, clusters 
of charged residues seem to be a frequent feature of the epi- 
topes bound by auto antibodies.  In fact, V.  Brendel et al. 
(26)  analyzed the charge properties of rheumatic disease- 
associated  autoantigens and found that clusters and/or runs 
of charged residues are significantly more frequent in these 
proteins than in other mammalian proteins. 
The potential functional relevance of this interaction is sug- 
gested by the observation that  three anti-DNA antibodies 
inhibited the enzyme activity of the molecule. Two of the 
three inhibitory antibodies  (P168 and Hy12) bound to the 
cyclic peptide corresponding to the active site, suggesting that 
the inhibition on DNase I was due to a specific reaction with 
this region of the molecule. The third antibody, H130,  did 
not recognize this peptide,  and we conclude that it either 
binds DNase I in a region close to the active loop and inter- 
feres with the activity of the enzyme through steric hindrance, 
or it induces a conformational change in the molecule that 
alters enzymatic activity. Nevertheless, the inhibition of DNase 
I enzymatic activity by either mechanism could have patho- 
logical implications by interference with DNase I activity at 
sites of inflammation. 
An immune response to DNase I  may also  amplify the 
production of anti-DNA antibodies through immune net- 
work interactions. For example, antiidiotypes could mimic 
DNAase  I  and  bind  DNA.  In  this  regard,  the  DNA- 
hydrolyzing antibodies described by A. M. Shuster et al. (27) 
may also represent such an idiotypic cascade. Similar examples 
have been described for other autoantibodies  (13,  14,  16). 
DNase I is a ubiquitous enzyme in mammalian tissues and 
is phylogeneticaUy highly conserved. Distribution studies (28, 
29) show that high levels of the enzyme can be detected in 
digestive tissues, such as the parotid and submaxillary glands 
and the lining of small intestine. Appreciable levels of  DNase 
I can be found in the kidney, where the enzyme probably 
plays a scavenging role, and in the lymph node and thymus 
(30). M. C. Peitsch et al. (30) demonstrated that the apoptosis- 
specific endonuclease, extractable from both thymocytes and 
lymph node cells, is functionally and antigenically indistin- 
guishable from DNase I. 
The dual specificity of anti-DNA antibodies  suggests a role 
of DNase I in the origin of anti-DNA antibodies. We pro- 
pose that anti-DNA antibodies arise from an immune response 
to a complex of DNA with the DNA-binding protein. Pep- 
tides from the protein moiety of the complex could elicit 
a T cell response. Such peptide-specific T cells can preferen- 
1802  Anti-DNA Antibodies Bind  to DNase  I tially help B cell clones that, through their surface Ig receptors, 
capture the DNA-protein complex and present DNase I pep- 
tides in association with MHC class II molecules.  B cells, 
whose surface Ig bind DNA, the DNA-binding protein, or 
both, will thus be stimulated. B clones producing Ig with 
a dual specificity (DNA and DNase I, or Sm and DNA) bind 
the complex with high avidity and, therefore, are efficient 
APC. We suggest that this property is a selective advantage 
that leads to preferential expansion of B cell clones binding 
both DNA and DNA-binding protein. This hypothesis links 
several observations that have not so far been connected. Struc- 
tural studies have shown that lupus anti-DNA antibodies arise 
from antigen selection of somatically mutated B cells. Such 
a process is usually T cell driven, and, indeed, helper T cells 
a process is usually T cell driven, and, indeed, helper T cells 
that augment the anti-DNA response  have been identified 
(31-33).  However, T cells specific for oligonucleotides have 
never been reported. The relevant T  cell epitope may occur 
on DNA-binding nuclear proteins (34), a possibility strength- 
ened by the  observation that nucleoproteins with DNA- 
binding motifs are a frequent target of anti-DNA antibodies 
(35, 36) and that anti-native DNA antibodies can be induced 
by immunization with a protozoan DNA-binding polypep- 
tide (37). Among the DNA-binding proteins, DNase, which 
is so frequently  recognized by anti-DNA antibodies, may play 
a key role in the induction of the anti-DNA immune response. 
Additional studies using autoreactive B and T cell subsets 
and autoantibodies are planned to further address this issue. 
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